61 related articles for article (PubMed ID: 18953066)
21. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
[No Abstract] [Full Text] [Related]
22. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T
Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937
[TBL] [Abstract][Full Text] [Related]
23. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q
Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720
[TBL] [Abstract][Full Text] [Related]
24. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
25. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Hoskins JM; Goldberg RM; Qu P; Ibrahim JG; McLeod HL
J Natl Cancer Inst; 2007 Sep; 99(17):1290-5. PubMed ID: 17728214
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
28. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; RamÃrez J; Rudin CM; Vokes EE; Ratain MJ
J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
30. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
31. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
32. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
[TBL] [Abstract][Full Text] [Related]
33. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
34. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP
Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Hu ZY; Yu Q; Zhao YS
Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
